Why the study?
Does the use of sex-specific cutoffs for high-sensitivity cardiac troponin assays improve diagnosis and outcome prediction in patients with suspected acute coronary syndrome?
Does the use of sex-specific cutoffs for high-sensitivity cardiac troponin assays improve diagnosis and outcome prediction in patients with suspected acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
The routine use of sex-specific cutoffs for high-sensitivity troponin assays is questioned due to inconsistent clinical evidence and the potential to complicate diagnostic algorithms without clear prognostic benefit.
There are biological differences between males and females in cardiac structure and function that have been recently revealed using sensitive imaging techniques such as magnetic resonance tomography (1). With the availability of more sensitive assays capable of measuring extremely low concentrations of cardiac troponin, such biological differences may contribute to 99th percentile reference values for cardiac troponin that have been found to be lower in women than in men (2). Although it is still unclear whether clinical evidence is strong enough to support the use of sex-specific cutoffs in clinical practice, the Joint ESC/ACCF/AHA/WHF (European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation) Task Force for the Universal Definition of Myocardial Infarction already recommends the use of sex-specific cutoffs (3). However, there are several reasons to question such a general recommendation including a lack of consistent clinical evidence, the need to validate such criteria for each high-sensitivity (hs)2 cardiac troponin assay owing to potential analytical differences between assays, and the wide variation in 99th percentile values across commercially available cardiac troponin assays (4). These issues may confuse clinicians and translate into the incorrect incorporation of such limits into clinical routine as diagnostic algorithms become increasingly complicated. In particular, there are 5 relevant concerns that argue against such a recommendation and that require more elaboration. Clinical evidence supporting the use of sex-specific cutoffs is sparse and controversial. Application of sex-specific 99th percentile values (4) was reported to increase numbers of non-ST elevation myocardial infarctions (NSTEMIs) by 4.7%–11% in females depending on the hs–cardiac troponin assay used, but also to decrease numbers of NSTEMIs in males by 2%–3% (5–7). Whether diagnostic reclassification translates into improved prediction of outcomes is a matter of controversy with some studies reporting an unequivocal benefit (5) in contrast with others reporting no (6–8) or only a little clinical impact (9). In a retrospective register-based study on 48250 patients, Eggers et al. (6) found no evidence for a better risk prediction using sex-specific 99th percentiles. Consistent with this, a substudy of TRAPID-AMI (High-sensitivity cardiac Troponin T assay for RAPID rule-out of Acute Myocardial Infarction) study on 1282 patients with suspected acute coronary syndrome (ACS) found no significant differences in outcome data when diagnoses were classified by sex-specific cutoffs (7). Cullen et al. (9) tested the performance of sex-specific cutoffs for prognostication of outcomes in an ACS population using the Abbott STAT hs-cTnI assay and found only marginal improvement of risk prediction. Interestingly, better outcome prediction was found at cutoffs substantially lower than the 99th percentile values (≥6 ng/L for women and ≥7 ng/L for men using ROC analyses, and ≥6 ng/L for women and ≥9 ng/L for men using logistic regression modeling). Therefore, Cullen et al. (9) recommended consideration of lowering the clinical cutoff for both sexes for prognostic purposes instead of using sex-specific 99th percentile values as recommended by the manufacturer. Consistent with this, the optimal cutoffs for a rapid 1-h NSTEMI rule-out and rule-in algorithm in suspected ACS were determined as <5 and ≤6 ng/L, respectively with the use of the same STAT Architect hs-cTnI assay in 2 other large ACS cohorts (10). The finding that lowered cutoffs proved superior for both sexes is important information that frames any discussion regarding the usefulness of much higher sex-specific cutoffs. In an attempt to explain discrepancies regarding diagnostic performance between various hs–cardiac troponin assays, Wildi et al. (11) found that approved clinical decision values were not biologically equivalent and contributed to major inconsistencies in the diagnosis of AMI. For instance, the biologically equivalent Abbott Architect hs-cTnI value corresponding to the approved clinical decision value for hs-cTnT was less than half of the approved clinical decision value for hs-cTnI. Reference populations are extremely heterogenous and 99th percentile values strongly depend on patient selection and definition of health (2, 4). An example of how 99th percentile values may vary across various reference populations is given by the Abbott STAT hs-cTnI assay that displays a huge range of 99th percentile values (Table 1), and largely divergent optimized decision cutoffs for diagnosis and prognostication in suspected ACS (10). As a consequence, sex-specific 99th percentile cutoff values have to be established and validated prospectively for each commercially available hs–cardiac troponin assay and every change of its formulation. From a statistical perspective, the absolute difference between the general 99th percentile cutoff and either sex-specific cutoff determines the numbers of reclassification in either direction. As demonstrated nicely by Shah et al., the strongest impact of sex-specific cutoffs is observed in the presence of larger differences between cutoffs (5). Not unexpectedly, effects in their study regarding diagnostic reclassification were significant and most dominant if sex-specific cutoffs using the Abbott Architect STAT hs-cTnI assay were compared to the general cutoffs using a contemporary sensitive formulation of cTnI (5). By contrast, for the hs-cTnT assay the 99th percentile value determined in numerous reference populations is narrow between 13.5 and 16 ng/L and the difference between sexes is small and only half of the mean absolute difference determined across different 99th percentile populations with the Abbott Architect hs-cTnI (mean difference 6.65 vs 13.4 ng/L) rendering reclassification more likely with hs-cTnI and very unlikely with Roche hs-cTnT (Table 1). Thus, recommendations for use of sex-specific 99th percentile cutoff values cannot be generalized and their need and usefulness has to be demonstrated individually for each commercially available cTnI assay. Clinical consequences after reclassification of a small MI that went undetected using a general cutoff are unclear, as are the potential therapeutic benefits from more aggressive coronary revascularization procedures and pharmacological treatments. Disease mechanisms associated with small increases in cardiac troponin are believed to differ between the sexes (6). Microvascular and endothelial dysfunction or diffuse coronary atherosclerosis is more common in women with lower cardiac troponin concentrations (12). Reported undertreatment of females with MI does not appear automatically inappropriate given that female sex is associated with a substantially higher prevalence of type 2 MI and nonobstructive coronary artery disease (CAD) (6, 13), and that women are more susceptible for bleeding complications (14). An increasing number of authors suggests the use of specific cutoffs among suspected ACS that not only should consider sex but also age (7), presenting symptoms, and renal function (15). Optimized algorithms might also need to implement specific relative or absolute concentration changes that differ from current recommendations. Such sophisticated algorithms lack clinical practicability and would further complicate the diagnostic algorithm by introduction of a multitude of cutoffs. Computers would be needed to determine the optimal individual cutoff and the magnitude of a relevant rise and or fall in most patients. Sex-specific 99th percentile values of hs-cTnT (Roche) and hs-cTnI (Abbott Architect) in selected studies [adapted from reference 10 (Giannitsis) and reference 16 (Koerbin et al.)]. There was a lot-to-lot variation with use of 6 affected hs-cTnT lots (lots 57120, 160197, and 163704 for the hs-cTnT 18 min assay, and lots 158268, 161334, 164773 for the hs-cTnT STAT assay) between 2010 to 2012 leading to downward shift in study participants with low hs-cTnT concentrations. Reference populations measured before and after this period including all reference studies listed in Table 1 were not affected. All samples. Different matrices. EDTA. Serum. Lithium-heparin plasma. Sex-specific 99th percentile values of hs-cTnT (Roche) and hs-cTnI (Abbott Architect) in selected studies [adapted from reference 10 (Giannitsis) and reference 16 (Koerbin et al.)]. There was a lot-to-lot variation with use of 6 affected hs-cTnT lots (lots 57120, 160197, and 163704 for the hs-cTnT 18 min assay, and lots 158268, 161334, 164773 for the hs-cTnT STAT assay) between 2010 to 2012 leading to downward shift in study participants with low hs-cTnT concentrations. Reference populations measured before and after this period including all reference studies listed in Table 1 were not affected. All samples. Different matrices. EDTA. Serum. Lithium-heparin plasma. Finally, there are some general concerns that need to be addressed. When considering the need for prospective validation of sex-specific cutoffs, it should be noted that general 99th percentile cutoffs have also not been prospectively validated, but still are regarded as the reference standard by many clinicians. We recommend an evidence-based and careful academic discussion on the future role of the general 99th percentile decision cutoff; any unsupported recommendation that further complicates the convenient diagnosis of MI by introducing specific cutoffs and Δ values adjusted for sex or comorbidities will likely confuse clinicians and lead to the misuse of hs–cardiac troponin assays in clinical routine. high-sensitivity non–ST elevation myocardial infarction High Sensitivity Cardiac Troponin T Assay for Rapid Rule-out of Acute Myocardial Infarction acute coronary syndrome coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Evangelos Giannitsis (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: